World Investment Advisors Buys New Shares in Royalty Pharma PLC $RPRX

World Investment Advisors purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 48,256 shares of the biopharmaceutical company’s stock, valued at approximately $1,702,000.

Several other hedge funds have also recently made changes to their positions in the business. Swedbank AB lifted its stake in shares of Royalty Pharma by 0.4% in the 3rd quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock valued at $430,426,000 after purchasing an additional 42,800 shares during the period. State Street Corp grew its stake in Royalty Pharma by 7.1% during the second quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock worth $367,324,000 after purchasing an additional 678,810 shares during the period. Geode Capital Management LLC increased its holdings in Royalty Pharma by 2.2% in the second quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock worth $299,494,000 after purchasing an additional 177,036 shares in the last quarter. Norges Bank acquired a new position in Royalty Pharma in the second quarter valued at approximately $181,388,000. Finally, Patient Capital Management LLC boosted its holdings in shares of Royalty Pharma by 0.5% during the 2nd quarter. Patient Capital Management LLC now owns 2,987,988 shares of the biopharmaceutical company’s stock worth $107,657,000 after buying an additional 15,342 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP George W. Lloyd sold 132,426 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $38.34, for a total transaction of $5,077,212.84. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Terrance P. Coyne sold 69,594 shares of Royalty Pharma stock in a transaction on Monday, November 17th. The stock was sold at an average price of $39.30, for a total transaction of $2,735,044.20. Following the transaction, the chief financial officer directly owned 54,760 shares in the company, valued at $2,152,068. This represents a 55.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 826,511 shares of company stock valued at $32,224,604 over the last 90 days. Insiders own 18.90% of the company’s stock.

Wall Street Analyst Weigh In

RPRX has been the subject of several research analyst reports. Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research note on Thursday, December 11th. TD Cowen upped their price objective on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Morgan Stanley cut their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group started coverage on Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Royalty Pharma Stock Down 0.1%

Shares of NASDAQ RPRX opened at $39.22 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The company has a 50-day moving average price of $38.66 and a 200-day moving average price of $36.96. The stock has a market capitalization of $22.64 billion, a P/E ratio of 29.71, a P/E/G ratio of 2.06 and a beta of 0.47. Royalty Pharma PLC has a 1 year low of $25.18 and a 1 year high of $41.24.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. On average, equities research analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is currently 66.67%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.